Zoetis Inc. (NYSE:ZTS) today announced that it has agreed to sell $1.850 billion of senior notes, consisting of $850.0 ...

Shares of Zoetis have been roughly average performers over the past decade. The shares seem appealingly valued at recent ...

The reality is that people and animals will always need medicine, treatments, and other products to live long and comfortable ...

Zoetis stock reversed Tuesday, sinking into the red, despite beating second-quarter expectations as Librela sales continued ...

Animal health company Zoetis (NYSE:ZTS) reported in Q2 CY2025, with sales up 4.2% year on year to $2.46 billion. The company ...

Zoetis raised annual forecast and beat second-quarter estimates on Tuesday, driven by strong demand for its medicines and ...

Shares of Zoetis Inc. ZTS slipped 1.46% to $148.81 Wednesday, on what proved to be an all-around grim trading session for the ...

Zoetis Inc. closed 25.61% short of its 52-week high of $200.33, which the company reached on September 19th.

Zoetis's leadership, scale, and innovation position it well against new competitors. Click here to read more about ZTS stock and why it is a Buy.

Zoetis enjoys enviable financial flexibility, even as leverage ticked up in 2015 to finance the purchase of Pharmaq and Abbott's animal health business. With long-term debt at roughly $5.2 billion ...

Zoetis, a leading animal health company, has shown impressive growth with a 17.55% CAGR since its IPO. Read why I rate ZTS stock a Buy now.

Breed Explorer offers veterinarian-approved, science-backed insights to help current and prospective pet owners make informed ...